Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy

NCT00968851 is registered in ClinicalTrials.gov with FORUM Pharmaceuticals Inc as lead sponsor.

NCT NCT00968851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00968851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Lead sponsor
FORUM Pharmaceuticals Inc
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2009
Completion date
March 31, 2011
Enrollment
317 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system diseases, cognition, schizophrenia